LONN Stock Analysis: Lonza | SW
Diagnostics & Research | SW, Switzerland | Market Cap: 39.350m CHF | 12M Return: 6.3% | CH0013841017 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 67.1M
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Lonza Group AG is a Swiss-headquartered contract development and manufacturing organization (CDMO) that provides outsourced services to pharmaceutical and biotechnology companies worldwide. Founded in 1897 and based in Basel, Switzerland, the company operates through three main segments: Integrated Biologics (clinical development, drug substance, and drug product manufacturing for biologics), Advanced Synthesis (manufacturing of antibody-drug conjugates, bioconjugates, small molecules, and highly potent active pharmaceutical ingredients), and Specialized Modalities (cell and gene therapies, microbial, bioscience, and mRNA technologies).
The CDMO business model enables drug developers to outsource complex manufacturing processes, allowing them to focus resources on research and development while leveraging specialized production capabilities. Lonzas Basel location situates the company in one of Europes most prominent pharmaceutical and biotechnology hubs, providing proximity to many of its largest clients.
- Biologics CDMO demand drives Integrated Biologics segment revenue growth
- ADC and bioconjugates capacity expansion fuels Advanced Synthesis margins
- Cell and gene therapy investments pressure near-term profitability
| Net Income: -110.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 2.31 > 1.0 |
| NWC/Revenue: 43.67% < 20% (prev 21.95%; Δ 21.72% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.44b > Net Income -110.0m |
| Net Debt (4.04b) to EBITDA (2.15b): 1.87 < 3 |
| Current Ratio: 1.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.9m) vs 12m ago -2.00% < -2% |
| Gross Margin: 36.53% > 18% (prev 32.61%; Δ 3.92% > 0.5%) |
| Asset Turnover: 34.15% > 50% (prev 34.84%; Δ -0.69% > 0%) |
| Interest Coverage Ratio: 13.18 > 6 (EBIT TTM 1.55b / Interest Expense TTM 118.0m) |
| A: 0.15 (Total Current Assets 6.94b - Total Current Liabilities 4.17b) / Total Assets 18.3b |
| B: 0.50 (Retained Earnings 9.10b / Total Assets 18.3b) |
| C: 0.08 (EBIT TTM 1.55b / Avg Total Assets 18.5b) |
| D: 0.80 (Book Value of Equity 8.12b / Total Liabilities 10.1b) |
| Altman-Z'' = 4.03 = AA |
| DSRI: 1.10 (Receivables 1.92b/1.80b, Revenue 6.33b/6.55b) |
| GMI: 0.89 (GM 32.61% / 36.53%) |
| AQI: 0.51 (AQ_t 0.15 / AQ_t-1 0.30) |
| SGI: 0.97 (Revenue 6.33b / 6.55b) |
| TATA: -0.09 (NI -110.0m - CFO 1.44b) / TA 18.3b) |
| Beneish M = -3.37 (Cap -4..+1) = AA |
As of October 10, 2026, the stock is trading at CHF 572.20 with a total of 77,924 shares traded. Over the past week, the price has changed by +1.17%, over one month by +6.36%, over three months by -1.79% and over the past year by +6.25%.
Current recommended Stop Loss: 548.70 (which is 4.1% or 1.9 ATR below the current price).
Lonza has no consensus analysts rating.
P/E Trailing = 38.2485
P/E Forward = 25.0627
P/S = 5.727
P/B = 4.8323
P/EG = 1.0118
Revenue TTM = 6.33b CHF
EBIT TTM = 1.55b CHF
EBITDA TTM = 2.15b CHF
Long Term Debt = 3.39b CHF (from longTermDebt, last quarter)
Short Term Debt = 774.0m CHF (from shortTermDebt, last quarter)
Debt = 4.52b CHF (from shortLongTermDebtTotal, last quarter) + Leases 355.0m
Net Debt = 4.04b CHF (calculated: Debt 4.52b - CCE 487.0m)
Enterprise Value = 43.4b CHF (39.4b + Debt 4.52b - CCE 487.0m)
Interest Coverage Ratio = 13.18 (Ebit TTM 1.55b / Interest Expense TTM 118.0m)
EV/FCF = 266.2x (Enterprise Value 43.4b / FCF TTM 163.0m)
FCF Yield = 0.38% (FCF TTM 163.0m / Enterprise Value 43.4b)
FCF Margin = 2.58% (FCF TTM 163.0m / Revenue TTM 6.33b)
Net Margin = -1.74% (Net Income TTM -110.0m / Revenue TTM 6.33b)
Gross Margin = 36.53% ((Revenue TTM 6.33b - Cost of Revenue TTM 4.02b) / Revenue TTM)
Gross Margin QoQ = 38.38% (prev 34.42%)
Tobins Q-Ratio = 2.38 (Enterprise Value 43.4b / Total Assets 18.3b)
Interest Expense / Debt = 2.61% (Interest Expense 118.0m / Debt 4.52b)
Taxrate = 17.83% (229.0m / 1.28b)
NOPAT = 1.28b (EBIT 1.55b * (1 - 17.83%))
Current Ratio = 1.66 (Total Current Assets 6.94b / Total Current Liabilities 4.17b)
Debt / Equity = 0.56 (Debt 4.52b / totalStockholderEquity, last quarter 8.12b)
Debt / EBITDA = 1.87 (Net Debt 4.04b / EBITDA 2.15b)
Debt / FCF = 24.75 (Net Debt 4.04b / FCF TTM 163.0m)
Total Stockholder Equity = 8.80b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.59% (Net Income -110.0m / Total Assets 18.3b)
RoE = -1.25% (Net Income TTM -110.0m / Total Stockholder Equity 8.80b)
RoCE = 12.75% (EBIT 1.55b / Capital Employed (Equity 8.80b + L.T.Debt 3.39b))
RoIC = 8.79% (NOPAT 1.28b / Invested Capital 14.5b)
WACC = 6.59% (E(39.4b)/V(43.9b) * Re(7.10%) + D(4.52b)/V(43.9b) * Rd(2.61%) * (1-Tc(0.18)))
Discount Rate = 7.10% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -85.88 | Cagr: -2.73%
[DCF] Terminal Value 75.44% ; FCFF base≈163.0m ; Y1≈163.7m ; Y5≈173.4m
[DCF] Fair Price = N/A (negative equity: EV 2.70b - Net Debt 4.04b = -1.34b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: -78.19 | Revenue CAGR: -3.57% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=18.53 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+23.3% | GrowthRev=+9.0%
EPS next Year (2027-12-31): EPS=22.06 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+19.0% | GrowthRev=+11.5%
[Analyst] Revisions Ratio: -40% (up=0, down=2)